Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.59 |
| ▸ | RXRB | P28702 | 1/20 | 0.59 |
| ▸ | RXRG | P48443 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488261 | 1.00 | RXRA (0.59) | RXRARXRBRXRGS1PR1AR | |
| SCHEMBL2328507 | 0.88 | RXRA (0.47) | RXRARXRBRXRGS1PR1AR | |
| SCHEMBL14328002 | 0.85 | RXRA (0.57) | RXRARXRBRXRGS1PR1CTSS | |
| SCHEMBL26291337 | 0.85 | RXRA (0.44) | RXRARXRBRXRGS1PR1AR | |
| SCHEMBL932902 | 0.84 | RXRA (0.56) | RXRARXRBRXRGS1PR1CTSS | |
| SCHEMBL2415055 | 0.84 | RXRA (0.59) | RXRARXRBRXRGS1PR1CTSS | |
| SCHEMBL247961 | 0.84 | CSNK2A1 (0.59) | RXRARXRBRXRGS1PR1CTSS | |
| SCHEMBL26179843 | 0.83 | RXRA (0.54) | RXRARXRBRXRGS1PR1CTSS | |
| SCHEMBL10088920 | 0.83 | RXRA (0.42) | RXRARXRBRXRGS1PR1AR | |
| SCHEMBL1437536 | 0.81 | S1PR1 (0.58) | RXRARXRBRXRGS1PR1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102884064-A | Process for preparing S1P1 receptor modulators and crystalline forms thereof | ARENA PHARM INC | 2013-01-16 | — | — | CN | claimed |
| EP-2542554-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2013-01-09 | — | — | EP | claimed |
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | claimed |
| WO-2011109471-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4444697-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11555015-B2 | Compounds useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210340104-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| EP-3847158-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| CN-112955431-A | Compounds useful for the treatment of autoimmune and inflammatory disorders | 艾尼纳制药公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-102197038-A | Substituted tricyclic acid derivatives as S1P1 receptor agonists for the treatment of autoimmune and inflammatory disorders | ARENA PHARM INC | 2011-09-21 | — | — | CN | disclosed |
| WO-2011109471-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109471-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-2354134-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | Astellas Pharma Inc. (JP) | 2011-08-10 | — | — | EP | disclosed |
| EP-2342205-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals ,Inc. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010027431-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555015-B2 | Compounds useful in the treatment of autoimmune and inflammatory disorders | S1PR1, S1PR5, S1PR3 | RXRA 669/4885RXRB 736/4885RXRG 868/4885 |
| US-20210340104-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | RXRA 669/4885RXRB 736/4885RXRG 868/4885 |
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, S1PR2, LPAR5 | RXRA 2022/4885RXRB 1684/4885RXRG 1591/4885 |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | RXRA 782/4885RXRB 733/4885RXRG 435/4885 |
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | S1PR1, S1PR5, S1PR2 | RXRA 1023/4885RXRB 1049/4885RXRG 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.